breast cancer HER 2 negative | ||
es-BC - HER2 negative - (neo)adjuvant (NA) | mBC - HER 2 negative | |
anti-PD-(L)1 | ||
durvalumab based treatment | ||
durvalumab alone | Saphir02 Breast-Immuno | |
pembrolizumab based treatment | ||
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | I-SPY2 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -